Patents Assigned to ImmuPharma (France) SA
-
Patent number: 10213482Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.Type: GrantFiled: December 11, 2015Date of Patent: February 26, 2019Assignees: ImmuPharma France SA, Centre National De La Recherche ScientifiqueInventors: Sylviane Muller, Robert H. Zimmer, Jean-Paul Briand
-
Patent number: 9657072Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.Type: GrantFiled: December 5, 2014Date of Patent: May 23, 2017Assignees: Centre National De La Recherche Scientifique, Immupharma France SAInventors: Sylviane Muller, Jean-Paul Briand, Robert H. Zimmer
-
Publication number: 20150111835Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.Type: ApplicationFiled: December 5, 2014Publication date: April 23, 2015Applicants: IMMUPHARMA FRANCE SA, CENTRE NATIONAL DE LA RECHERECHE SCIENTIFIQUEInventors: Sylviane Muller, Jean-Paul Briand, Robert H. Zimmer
-
Patent number: 8138145Abstract: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.Type: GrantFiled: February 18, 2010Date of Patent: March 20, 2012Assignees: Centre National de la Recherche Scientifique (SNRS), ImmuPharma France SAInventors: Aude Violette, Jean-Paul Briand, Robert H. Zimmer, Gilles Guichard
-
Publication number: 20100298206Abstract: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.Type: ApplicationFiled: February 18, 2010Publication date: November 25, 2010Applicants: Centre National de la Recherche Scientifique (CNRS), I.B.M.C., ImmuPharma France SA, TechnopoleInventors: Aude Violette, Jean-Paul Briand, Robert H. Zimmer, Gilles Guichard
-
Publication number: 20100291199Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.Type: ApplicationFiled: July 23, 2010Publication date: November 18, 2010Applicants: Centre National de la Recherche Scientifique (CNRS), ImmuPharma France SAInventors: Gilles Guichard, Gersande Lena, Eliette Lallemand, Laurent Renia
-
Patent number: 7777030Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.Type: GrantFiled: December 22, 2006Date of Patent: August 17, 2010Assignees: Centre National de la Recherge Scientifique (CNRS), ImmuPharma France SAInventors: Gilles Guichard, Gersande Lena, Eliette Lallemand, Laurent Renia
-
Patent number: 7691807Abstract: The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof.Type: GrantFiled: March 17, 2006Date of Patent: April 6, 2010Assignees: Centre National de la Recherche Scientifique (CNRS), ImmuPharma France SAInventors: Aude Violette, Jean-Paul Briand, Robert Zimmer, Gilles Guichard
-
Patent number: 7186739Abstract: A carbamate compound is disclosed.Type: GrantFiled: March 11, 2005Date of Patent: March 6, 2007Assignee: ImmuPharma (France) SAInventors: Gilles Guichard, Marie-Christine Galas-Rodriguez, legal representative, Pierre Rodriguez, legal representative, Elisa Rodriguez, legal representative, Romain Rodriguez, legal representative, Vincent Semetey, Jean-Paul Briand, Marc Rodriguez, deceased
-
Patent number: 7186828Abstract: A method for preparing cyclic urea compounds from at least an activated carbamic acid derivative containing an unprotected primary or secondary amine function, includes a cyclization step which consists in a reaction between the primary or secondary amine function and the carbamic acid function of the carbamic acid derivative(s).Type: GrantFiled: June 13, 2001Date of Patent: March 6, 2007Assignee: ImmuPharma (France) SAInventors: Gilles Guichard, Marie-Christine Galas-Rodriguez, legal representative, Pierre Rodriguez, legal representative, Elisa Rodriguez, legal representative, Romain Rodriguez, legal representative, Serge Plaue, Vincent Semetey, Arnaud-Pierre Schaffner, Jean-Paul Briand, Marc Rodriguez, deceased